WoWu Biological: The clinical trial application for the human umbilical cord mesenchymal stem cell type II injection drug by the holding subsidiary has been accepted.

2026-03-27 06:28:06

Iwu Biotech’s announcement: Its indirectly controlling subsidiary, Zhejiang Iwu Stem Cell Technology Co., Ltd. (hereinafter referred to as “Zhejiang Stem Cells”), has received an “Acceptance Notice” issued by the National Medical Products Administration (NMPA). The drug clinical trial application submitted by Zhejiang Stem Cells for “Human Umbilical Cord Mesenchymal Stem Cell Type II Injection” has been formally accepted.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.